Featured Research

from universities, journals, and other organizations

Promising new option for first line of attack in lymphoma

Date:
February 25, 2014
Source:
Manchester University
Summary:
Follicular lymphoma is a type of non-Hodgkin’s lymphoma -– a blood cancer -- that usually develops slowly. The majority of patients are diagnosed when their disease is at an advanced stage. Recent improvements in treatment have included the use of antibodies to specifically target the tumor cells and to stimulate the patient’s own immune system to attack their tumor. The use of such antibodies has improved treatment response, but unfortunately most patients still relapse Radioimmunotherapy -- where a radioactive substance is attached to the antibody -- has been shown to be successful in treating patients who had previously relapsed.

A study led by Manchester scientists has shown promising results for a new treatment approach in follicular lymphoma.

Follicular lymphoma is a type of non-Hodgkin's lymphoma- a blood cancer -- that usually develops slowly. The majority of patients are diagnosed when their disease is at an advanced stage.

Recent improvements in treatment have included the use of antibodies to specifically target the tumor cells and to stimulate the patient's own immune system to attack their tumor.

The use of such antibodies has improved treatment response, but unfortunately most patients still relapse.

Radioimmunotherapy -- where a radioactive substance is attached to the antibody -- has been shown to be successful in treating patients who had previously relapsed.

Now a team involving researchers from The University of Manchester -- part of the Manchester Cancer Research Centre -- has investigated the use of radioimmunotherapy treatment in newly diagnosed patients.

The study published in the Journal of Clinical Oncology, looked at the effect of delivering the treatment in two fractions or doses -- this approach is thought to improve the penetration of the drug within larger tumors and also helps reduce the side effects associated with a full dose treatment.

Professor Tim Illidge, who led the research, said: "This was the first study to look at giving two fractions of radioimmunotherapy as an initial treatment in follicular lymphoma. We wanted to assess its safety and effectiveness in a group of high-risk patients who conventionally have done less well."

The researchers found that that their treatment plan was feasible and safe, with very few side effects.

"We saw a high overall response rate, of 94.4%, and 50 of the 72 (69.4%) patients treated in the study achieved complete response -- meaning their symptoms disappeared. These results are encouraging, but we need further studies in larger numbers of patients to fully compare this treatment to the standard treatment of 6-8 cycles of chemotherapy," added Professor Illidge.


Story Source:

The above story is based on materials provided by Manchester University. Note: Materials may be edited for content and length.


Journal Reference:

  1. T. M. Illidge, S. Mayes, R. Pettengell, A. T. Bates, M. Bayne, J. A. Radford, W. D. J. Ryder, S. Le Gouill, F. Jardin, J. Tipping, M. Zivanovic, F. Kraeber-Bodere, M. Bardies, C. Bodet-Milin, E. Malek, D. Huglo, F. Morschhauser. Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. Journal of Clinical Oncology, 2013; 32 (3): 212 DOI: 10.1200/JCO.2013.50.3110

Cite This Page:

Manchester University. "Promising new option for first line of attack in lymphoma." ScienceDaily. ScienceDaily, 25 February 2014. <www.sciencedaily.com/releases/2014/02/140225101250.htm>.
Manchester University. (2014, February 25). Promising new option for first line of attack in lymphoma. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2014/02/140225101250.htm
Manchester University. "Promising new option for first line of attack in lymphoma." ScienceDaily. www.sciencedaily.com/releases/2014/02/140225101250.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com
Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins